In the news release, "Rosetta Genomics Reports First Quarter 2008 Financial Results" issued on 21 May 2008 12:30 GMT, by Rosetta Genomics Ltd nasdaq:ROSG over PR Newswire, we are advised by a representative of the company that the time of the conference call, as stated beneath the header ‘Conference Call Information’, should be 4:30p.m. ET and not 8:30 a.m. ET as previously issued. Complete, corrected release follows:
Rosetta Genomics, Ltd. , a leading molecular diagnostics company, reported today its consolidated financial results for the quarter ended March 31, 2008 and business highlights.
The 2008 first-quarter net loss of $3.9 million (including a non-cash expense of $191,000 related to stock based compensation), or $0.33 per ordinary share. The first-quarter result compares with a net loss of $2 million (including a non-cash expense of $205,000 related to stock based compensation), or $0.23 per ordinary share, for the corresponding quarter of 2007.
"This has been a remarkable quarter for us at Rosetta Genomics on both the business and scientific fronts," said Amir Avniel, President and CEO of Rosetta Genomics. "We have continued the rapid advancements towards the launch of the first diagnostic tests based on our microRNA technology, and look forward to the exciting events that lay ahead of us in the following months."
On the business front, Rosetta Genomics recently announced that Columbia University Medical Center’s Molecular Pathology Laboratory has submitted the first microRNA-based test based on the company’s microRNA technology for regulatory approval to the New York State Department of Health. The test is designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) and is the first of three tests the company expects will be submitted for regulatory approval by CLIA certified labs in 2008.
In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta’s proprietary microRNA technology.
On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.
Financial Overview
Operating loss for the first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.
Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company’s largest expense and accounted for 64% of its operating losses.
As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.
As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two are rated AAA. However, due to the continuing uncertainty in the credit market, the company recorded an impairment of $300,000 during the first quarter.
Recent Highlights
Rosetta Genomics reports the following scientific and corporate highlights:
Diagnostic Programs
- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Columbia University Medical Center’s Molecular Pathology Laboratory has submitted this test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using a single microRNA, for regulatory approval to the New York State Department of Health. The approval process is estimated to take 2-6 months.
The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Bevacizumab, an angiogenesis inhibitor and an important new modality of therapy for non-squamous NSCLC, includes a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC.
- Mesothelioma vs. Adenocarcinoma - Differentiating between mesothelioma and adenocarcinoma is critical for optimal therapy, but it is often difficult to differentiate these tumors. Currently, there is no objective, standardized test to aid pathologists in differentiating between the many possible tumors in the lung and pleura. Based on a few microRNA biomarkers that were identified applying Rosetta Genomics’ technology, a test is being developed to separate mesothelioma from adenocarcinoma tumors including lung adenocarcinoma and metastases to the lung or to the pleura. This test is expected to be filed for regulatory approval in H2 2008.
Information provided by: Findarticles.com
First Diagnostic Test Based on Company’s microRNA Technology Submitted for Regulatory Approval to the New York State Department of Health by Columbia University Medical Center
Additional West Coast Clinical Laboratory to Validate and Offer Tests Based on Rosetta Genomics’ microRNA Technology
Two Additional microRNA-Related Patents Allowed
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, May 21 /PRNewswire-FirstCall/ — Rosetta Genomics, Ltd. , a leading molecular diagnostics company, reported today its consolidated financial results for the quarter ended March 31, 2008 and business highlights.
The 2008 first-quarter net loss of $3.9 million (including a non-cash expense of $191,000 related to stock based compensation), or $0.33 per ordinary share. The first-quarter result compares with a net loss of $2 million (including a non-cash expense of $205,000 related to stock based compensation), or $0.23 per ordinary share, for the corresponding quarter of 2007.
"This has been a remarkable quarter for us at Rosetta Genomics on both the business and scientific fronts," said Amir Avniel, President and CEO of Rosetta Genomics. "We have continued the rapid advancements towards the launch of the first diagnostic tests based on our microRNA technology, and look forward to the exciting events that lay ahead of us in the following months."
On the business front, Rosetta Genomics recently announced that Columbia University Medical Center’s Molecular Pathology Laboratory has submitted the first microRNA-based test based on the company’s microRNA technology for regulatory approval to the New York State Department of Health. The test is designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) and is the first of three tests the company expects will be submitted for regulatory approval by CLIA certified labs in 2008.
In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta’s proprietary microRNA technology.
On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.
Financial Overview
Operating loss for the first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.
Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company’s largest expense and accounted for 64% of its operating losses.
As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.
As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two are rated AAA. However, due to the continuing uncertainty in the credit market, the company recorded an impairment of $300,000 during the first quarter.
Recent Highlights
Rosetta Genomics reports the following scientific and corporate highlights:
Diagnostic Programs
- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Columbia University Medical Center’s Molecular Pathology Laboratory has submitted this test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using a single microRNA, for regulatory approval to the New York State Department of Health. The approval process is estimated to take 2-6 months.
The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Bevacizumab, an angiogenesis inhibitor and an important new modality of therapy for non-squamous NSCLC, includes a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC.
- Mesothelioma vs. Adenocarcinoma - Differentiating between mesothelioma and adenocarcinoma is critical for optimal therapy, but it is often difficult to differentiate these tumors. Currently, there is no objective, standardized test to aid pathologists in differentiating between the many possible tumors in the lung and pleura. Based on a few microRNA biomarkers that were identified applying Rosetta Genomics’ technology, a test is being developed to separate mesothelioma from adenocarcinoma tumors including lung adenocarcinoma and metastases to the lung or to the pleura. This test is expected to be filed for regulatory approval in H2 2008.
Information provided by: Findarticles.com
Kuala Lumpur, May 21, 2008 - (ACN Newswire) - Following negotiations on a synergistic collaboration, MESDAQ-listed SCAN Associates Berhad ("SCAN"), Malaysia’s leading ICT security solutions provider, today cemented its intention to expand its offerings under its Managed Security Services ("MSS") segment following a Document Exchange Ceremony with AhnLab Inc. ("AhnLab"), the largest Korean IT security provider listed on the KOSDAQ stock exchange of Korea. The symbolic ceremony marks the intention of both parties to jointly collaborate in research and development of network security devices for the purpose of eventually developing a product or system on an Original Equipment Manufacturing ("OEM") arrangement.
The Document Exchange Ceremony was held in conjunction with the World Congress for Information Technology 2008 event ("WCIT 2008") currently ongoing at the Kuala Lumpur Convention Centre, marking it as the first technology-related collaboration initiative between two companies involved in the provision of ICT security services from the respective countries. Deputy Prime Minister Dato’ Seri Najib Tun Abdul Razak was present to witness the event which was organized by the Multimedia Development Corporation Berhad ("MDeC").
Commenting on the collaboration, Group Chief Executive Officer of SCAN, Dato’ Aminuddin Baki Esa said, "Our strategic technology collaboration with AhnLab is in line with our plans to enhance offerings in the areas of Security Software Management and Hosted Services under our MSS segment. Devices such as Firewall, Intrusion Detection System, Intrusion Prevention System, anti-virus, e-mail filtering and web-content filtering, will be developed as a "Unified Threat Management System", a single device for IT network security which will allow us to offer our customers a trusted solution for preventing cyber attacks, while providing another layer of value-add for improving operational efficiency."
SCAN has recorded strong growth in its MSS market in 2007. In the MSS segment, revenue growth was approximately 18 per cent, i.e. from RM9.5 million in FY06 to RM11.2 million in FY07. It also registered double-digit subscriber growth in the MSS market of more than 15 per cent year-on-year. The bulk of the increase was mainly due to the increase in subscriber base from banking & finance, and the telco sector especially in Indonesia. Revenue growth from these segments increased to RM2.6 million and RM4.4 million respectively in FY07 (FY06: RM0.991 million and RM2.3 million respectively). This contributed a very encouraging growth of about 159 per cent and 94 per cent respectively.
SCAN currently offers Managed Security Services (’MSS’) covering areas such as Device Management [for e.g. Firewall, Intrusion Detection System and Intrusion Prevention System devices] and professional consultancy services (for e.g. 24 x 7 Monitoring Surveillance, Vulnerability Assessment, Penetration Testing, Security Policy Implementation, Security Posture Assessment).
"We have made our mark in the Middle East and South East Asia, while AhnLab has a strong presence in East Asian countries. Hence, this partnership will enable both parties to expand their overseas business by tapping into each other’s markets. This strategy is expected to contribute positively to SCAN’s bottom-line, particularly in our recurring income, in the next few years," added Datof Aminuddin.
At the Document Exchange Ceremony, SCAN was represented by Datof Aminuddin. Meanwhile, AhnLab was represented by its General Manager for Global Business, Mr Ho Chul Shin and Mr Duk Young Jung, Business Development Manager for Global Business.
Home-grown SCAN is a leading company in the MSS market in Malaysia. SCAN captured the Frost & Sullivan Malaysiafs Telecoms Award for Managed Security Service Provider of the Year for 2006 and 2007. The Company provides essential support to the national ICT agenda via its end-to-end solutions to private and public sectors covering a broad range of segments. These areas include ICT security applications development, ICT security application software packages, ICT security consultancy, ICT security systems integration, provision of outsourcing services or MSS, and provision of maintenance and ICT security training services
About AhnLab Inc.
AhnLab Inc., which has its headquarters in Seoul, Korea, develops industry-leading solutions designed to secure and protect information. Innovating the information security world since 1988, AhnLab’s products and services have always been designed to meet the needs of enterprises and consumers alike. En route to becoming the largest security provider in Korea, AhnLab established their V3 product family as the industry-standard for information protection. Additional solutions such as mobile device protection, online-driven consumer security, and enterprise consulting services have enabled AhnLab to grow at an incredible pace.
Information provided by: Findarticles.com
KENILWORTH, N.J., May 21 /PRNewswire-FirstCall/ — Schering-Plough Corporation , a leader in hepatitis research, today announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus (HCV) genotype 1. One study will be in previously untreated (naive) patients and the other in patients who failed prior treatment (relapsers and nonresponders), an area of great unmet medical need. The two randomized, double-blind, placebo-controlled studies will evaluate the efficacy of boceprevir in combination with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) compared to standard of care with PEGINTRON and REBETOL alone. The Company said the two pivotal studies will run concurrently and are projected to enroll a total of more than 1,400 patients at U.S. and international sites.
"We are excited to advance to Phase III clinical studies with boceprevir in combination with PEGINTRON and REBETOL," said Fred Poordad, M.D., chief of hepatology in the division of gastroenterology at Cedars-Sinai Medical Center, associate professor of medicine at the David Geffen School of Medicine, University of California, Los Angeles (UCLA), and co-principal investigator of the Phase III study in naive patients. "These studies are designed to demonstrate that this combination therapy has the potential to benefit a broad range of patients by significantly increasing sustained response rates with a potentially shorter course of treatment."
In both Phase III clinical studies, patients will receive 4 weeks of treatment with PEGINTRON and REBETOL prior to the addition of boceprevir. The rationale for this novel treatment paradigm is based on the fact that both PEGINTRON and REBETOL reach steady-state concentrations by week 4, so patients have the protease inhibitor added at a time when the backbone drug levels have been optimized. In addition, the patient’s immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. This approach may minimize the period of time when there is a "functional monotherapy" with a direct antiviral, and may help reduce the likelihood for the development of resistance by identifying patients who are responders to interferon and ribavirin prior to their receiving a protease inhibitor.
Pivotal Study in Previously Untreated (Naive) Patients
The primary objective of this pivotal study, known as HCV SPRINT-2 (HCV Serine Protease Inhibitor Therapy-2), is to evaluate the efficacy of 28- and 48-week regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in previously untreated (naive) adult patients with chronic HCV genotype 1. The study is projected to enroll a total of more than 1,000 patients, including a minimum of 150 African-American/Black patients.
In this study, in the 28-week treatment arm, rapid viral response (RVR) criteria at 4 weeks of boceprevir treatment (treatment week 
will be used to determine which boceprevir patients can stop all treatment at 28 weeks. Patients in the 28-week boceprevir arm who achieve RVR, defined as undetectable virus (HCV-RNA) in plasma at week 4 of boceprevir treatment, will stop all treatment at week 28. Patients who do not meet the RVR criteria will stop boceprevir treatment at week 28 and continue PEGINTRON and REBETOL alone for an additional 20 weeks, for a total treatment duration of 48 weeks. In the 48-week treatment arm, patients will receive PEGINTRON and REBETOL plus boceprevir for a total treatment duration of 48 weeks. Patients in any arm of this study with detectable virus at week 24 will be considered treatment failures and will discontinue treatment.
The primary efficacy endpoint of the study is sustained virologic response (SVR).(1) Secondary efficacy endpoints include early virologic response in patients who achieve SVR. The study will be stratified by HCV genotype 1 subtype 1a versus 1b, and baseline viral load.
Professor Jean-Pierre Bronowicki, M.D., Ph.D., department of hepato-gastroenterology, University Hospital of Nancy, France, and Jonathan McCone, M.D., director, Mount Vernon Endoscopy Center, Alexandria, Va., are the other co-principal investigators of this study.
Pivotal Study in Patients Who Failed Prior Treatment
The primary objective of this pivotal study, known as HCV RESPOND-2 (Retreatment with HCV Serine Protease Inhibitor Boceprevir and PEGINTRON/REBETOL) is to evaluate the efficacy of 36- and 48-week regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in adult patients with chronic HCV genotype 1 who failed prior treatment with peginterferon and ribavirin combination therapy. The study is projected to enroll a total of 375 patients.
Information provided by: Findarticles.com
SOUTH SAN FRANCISCO, Calif. — Cell Genesys, Inc. (Nasdaq:CEGE) today reported encouraging interim data from the expansion cohort of the Phase 1, multicenter clinical trial of CG0070 in patients with recurrent superficial bladder cancer who had failed therapy with Bacillus Calmette-Guerin (BCG), the current standard of care for this patient population. Sixteen patients have completed dosing of CG0070 administered once weekly or once every four weeks at the two lowest of three doses being evaluated. Ten of these sixteen patients showed anti-tumor activity as measured by complete response at follow-up cystoscopy. These data were presented by James M. McKiernan, M.D., vice chairman of urology and assistant professor of urology at Columbia University College of Physicians and Surgeons, at the annual meeting of the American Urological Association being held in Orlando, Florida.
"We are encouraged to see that these additional data support earlier Phase 1 findings that suggest oncolytic virus therapy CG0070 may result in anti-tumor activity in patients with recurrent superficial bladder cancer," stated Robert J. Dow, MBChB, senior vice president of Medical Affairs and chief medical officer of Cell Genesys. "We plan to evaluate the data for the remaining patients on this trial and then, together with our partner Novartis AG, determine the next steps for this program."
The Phase 1, open label, dose-escalation trial was designed to evaluate intravesical (into the bladder) administration of CG0070 in patients with superficial bladder cancer who had failed previous therapy with BCG. The trial, which has enrolled a total of 35 patients, was designed to first evaluate escalating single-dose levels of CG0070 and was then expanded to evaluate escalating multiple dose regimens administered once weekly or once every four weeks. The primary endpoints of the study were safety and the determination of a maximum tolerated dose. Other endpoints included clinical response based on follow-up cystoscopy and recurrence-free survival.
Twenty-two patients have been enrolled into the dose expansion cohort of the trial. Sixteen patients enrolled into the two lowest of three dose groups have completed dosing of CG0070 administered once weekly or once every four weeks. An additional six patients have been enrolled at the third dose level at both dosing schedules and are currently being dosed. Evidence of anti-tumor activity documented by a complete response at follow-up cystoscopy performed at approximately three months following administration of CG0070 was observed in the two lowest dose cohorts at both dosing schedules. Five of six patients who received CG0070 administered once weekly, three of whom were in the first (lowest) dose cohort, experienced a complete response, and five of 10 patients who received CG0070 once every four weeks, of whom three were in the first dose cohort, experienced a complete response. Patients treated at the first dose level all had incompletely resected tumor remaining in their bladder at the time of initial dosing. The longest response durations measured for the weekly and every four-week schedules were continuing at 10.4 months and 7.5 months, respectively. Multi-dose administration of intravesical CG0070 has a generally tolerable safety profile with predominantly local toxicities. Grade 3 adverse events included transient reduction of lymphocyte count, asymptomatic elevation of coagulation tests and urinary frequency and urgency.
About Bladder Cancer
The American Cancer Society estimates that approximately 69,000 new cases of bladder cancer will be diagnosed in 2008, and that the majority of these are superficial bladder cancer. Superficial bladder cancer has traditionally been treated by transurethral resection (TUR) upon initial diagnosis, but unfortunately is marked by recurrence in the majority of patients. The current standard therapy after TUR is intravesical BCG. Patients with superficial bladder cancer who fail BCG have limited options. Historically, cystectomy has been the standard of care in this setting. Intravesical chemotherapeutic agents have been tried but with limited efficacy. Additional therapies for recurrent bladder cancer are needed in order to decrease treatment morbidity, increase bladder preservation, and improve long term outcomes.
About Oncolytic Virus CG0070
Oncolytic Virus CG0070 is an investigational product for the treatment of recurrent bladder cancer. CG0070 is comprised of adenoviruses, a cause of the common cold, which have been engineered to replicate in and destroy target cancer cells and to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), a potent immune cytokine. By secreting GM-CSF, CG0070 holds the potential to stimulate a systemic anti-tumor immune response following local administration. Cell Genesys is developing CG0070 in partnership with Novartis AG, pursuant to a global alliance formed between the companies in July 2003.
Information provided by: Findarticles.com
Award Recognizes the 100 ‘Most Promising’ Companies Driving the Future of Technology
SUNNYVALE, Calif., May 21 /PRNewswire/ — Proofpoint, Inc., the leading provider of unified email security and data loss prevention solutions, has been named as one of the winners of the 2008 Red Herring 100 Award, a selection of the 100 most innovative private technology companies based in North America.
"Proofpoint’s explosive growth is fueled by our continued focus on delivering the most advanced and innovative protection against both inbound and outbound messaging threats," said Proofpoint CEO Gary Steele. "The Red Herring 100 is yet another validation of Proofpoint’s leadership and innovation in the email security and data loss prevention market."
More than 1,600 enterprises worldwide rely on Proofpoint to protect both inbound and outbound messaging channels, reducing the risks associated with inbound threats such as spam and viruses, while guarding against compliance violations and leaks of confidential information. As the only email security and data loss prevention vendor that offers its security solutions in every form factor available — hardware appliance, virtual appliance, software and on-demand service — Proofpoint provides customers with the flexibility and agility they need to meet evolving messaging-security requirements.
The Red Herring editorial board diligently surveyed the entrepreneurial scene throughout the North American region and identified the top 100 out of more than 800 closely evaluated companies that are leading the next wave of innovation.
Try Proofpoint on Demand, Free for 30 Days
Experience the benefits of Proofpoint on Demand. Qualified organizations can try Proofpoint on Demand free of charge for 30 days. To get started, please visit:
http://www.proofpoint.com/trypod About Proofpoint, Inc.
Proofpoint provides unified email security and data loss prevention solutions for enterprises, universities, government organizations and ISPs to defend against inbound threats such as spam and viruses, prevent leaks of confidential and private information across all protocols, and encrypt sensitive emails. Proofpoint’s products are controlled by a single management and policy console and are powered by Proofpoint MLX(TM) technology, an advanced machine learning system developed by Proofpoint scientists and engineers. Proofpoint provides the most scalable and flexible deployment model including: hardware appliance, virtual appliance, hosted services and software. For more information, please visit http://www.proofpoint.com/.
Proofpoint, Proofpoint MLX, Proofpoint Messaging Security Gateway, Proofpoint Secure Messaging, Proofpoint Regulatory Compliance, Proofpoint Spam Detection and Proofpoint Virus Protection are trademarks, registered trademarks or licensed trademarks of Proofpoint, Inc. All other trademarks contained herein are the property of their respective owners.
CONTACT: Sharon Dratch of Davies Murphy Group, Inc., +1-781-418-2425, pr@proofpoint.com, for Proofpoint, Inc.
Web site: http://www.proofpoint.com/
COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning
Information provided by: Findarticles.com
IronPort® Systems — a leading provider of
enterprise spam, virus and spyware protection, and now part of Cisco
(NASDAQ: CSCO) — today announced that its high-performance security
solutions are helping its customers dramatically reduce their power
consumption and data center footprint. Not only is IronPort is helping
enterprises save money, but its products are also contributing positively
to its customers’ environmental initiatives. In fact, IronPort’s products
are currently in use by 95 percent of Fortune magazine’s 100 Most
“Accountable” Companies, which are ranked by their commitment to social and
environmental goals.
“Spam volumes continue to double annually and now completely dominate
legitimate mail volumes. Without spam-mitigation tools, enterprises would
need to double email capacity annually, a practically unbearable burden,”
said Peter Christy, founder of the Internet Research Group. “Effective spam
tools protect email resources, but these engines still require scaling to
deal with growing spam volumes. IronPort’s purpose-engineered mail
processors deliver significantly more throughput than competitive
alternatives; that translates into fewer spam servers and reduced power and
space requirements. This benefit is compounded by IronPort’s effective
reputation services, which drop most of the spam traffic at the network
connection level before the spam engines need to process it. On balance,
IronPort delivers leading spam mitigation per joule of energy invested, an
attribute of growing importance as both spam volumes and energy prices
continue to rise unabated.”
IronPort’s security products are 66 percent more effective than competing
solutions in reducing power consumption and data center footprint(1). The
company’s products are five to ten times faster than competitors’
offerings, enabling customers to replace multiple devices from other
manufacturers with a single, highly-efficient IronPort security appliance.
By developing extremely high-performance security appliances, IronPort
enables customers to use less power when scanning incoming content for
threats such as viruses, malware and spam. Edge filtering also stops more
malicious and suspicious content from entering an organization’s network,
requiring less storage of unnecessary data. These features translate into
real savings because customers are able to reduce power consumption and
their data center footprint.
“At IronPort, our focus has always been on creating a clean, safe Internet
experience for our customers,” said Tom Gillis, vice president of marketing
at IronPort. “Many of our customers have realized the benefits, both to
the bottom line and their social responsibilities, of utilizing IronPort’s
security appliances.”
Many top companies around the world are utilizing IronPort products.
IronPort customers include 95 of the top 100 Most “Accountable” Companies
as ranked by Fortune magazine, as well 42 percent of Fortune 100 companies.
“With our previous vendor, we needed a number of devices to ensure that our
network was secure. This configuration was not only expensive to deploy and
maintain, but it used a lot of valuable rack space,” said Frank Miller,
chief technical officer at BendBroadband. “IronPort has significantly
simplified our security infrastructure. With a single IronPort appliance,
we receive unsurpassed security services in a smaller footprint, allowing
us to save space in our data center.”
About IronPort Systems
IronPort Systems, now part of Cisco (NASDAQ: CSCO), is headquartered in San
Bruno, California. IronPort is the leading provider of anti-spam,
anti-virus and anti-spyware appliances for organizations ranging from small
businesses to the Global 2000. IronPort appliances utilize SenderBase®,
the world’s largest email and Web threat detection network and database.
IronPort products are innovative and easy-to-use — providing breakthrough
performance and playing a mission-critical role in a company’s network
infrastructure. To learn more about IronPort products and services, please
visit: http://www.ironport.com/ .
Copyright © 2008 Cisco Systems, Inc. All rights reserved. IronPort, the
IronPort logo and SenderBase are registered trademarks of Cisco Systems,
Inc. All other trademarks are the property of Cisco Systems, Inc. or their
respective owners. While every effort is made to ensure the information
given is accurate, Cisco does not accept liability for any errors or
mistakes which may arise. Specifications and other information in this
document may be subject to change without notice.
(1) Internal IronPort Research
For direct RSS Feeds of all Cisco news, please visit “News@Cisco” at the
following link:
http://newsroom.cisco.com/dlls/rss.html
Press / Analysts
If you are a reporter or analyst and want more information on IronPort
Systems please contact:
David Oro
IronPort Systems
707.558.8585
oro@ironport.com
Suzanne Matick
IronPort Systems
831.479.1888
smatick@ironport.com
Information provided by: Findarticles.com
People with a family history of shingles may have increased susceptibility to the disease, say researchers at the University of Texas Medical School at Houston.
Shingles, also known as herpes zoster, causes nerve pain that occurs when the chickenpox virus (varicella zoster) is reactivated in spinal nerves. Most adults carry the varicella zoster virus, but only 10 percent to 30 percent develop shingles, according to background information in the study.
There are a number of risk factors for shingles, including weakened immunity, older age and other illnesses. Stress, trauma, exposure to heavy metals and ethnicity may also play a role. Recent research has suggested genetic risk factors for shingles and other infectious diseases associated with a weakened immune system.
In this study, researchers compared 504 people treated for shingles between 1992 and 2005 to 523 people without shingles. Along with demographic data, both groups provided information about their personal and …
Information provided by: Findarticles.com
PARIS (AFP) — Scientists in Taiwan believe they can explain how a form of dengue fever, a mosquito-borne disease that is triggering widening concern, reaps its deadly toll.
Dengue is caused by four types of virus. Infection with any one of these viruses causes a mild fever and lifelong immunity to that strain.
But a secondary infection by a different strain boosts the risk of dengue haemorrhagic fever, with internal bleeding, which can progress to the life-threatening dengue shock syndrome.
It is still unclear how this secondary infection is able to cause such serious symptoms.
One of the known factors, though, is an over-reaction by part of the immune system — a “storm” by agents called cytokines, which run amok and cause tissue inflammation.
Reporting in Thursday’s issue of Nature, researchers led by Shie-Liang Hsieh of the National Yang-Ming University in Taipei say that the cytokine storm is …
Information provided by: Findarticles.com